Histone Deacetylase Inhibitor FK228 Activates Tumor Suppressor Prdx1 with Apoptosis Induction in Esophageal Cancer Cells

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Clinical Cancer Research

• Publication date

  2005-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-05-0840PMID 16278420
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impact of novel histone deacetylase inhibitors, CHAP31 and FR901228 (FK228), on adenovirus‐mediated transgene expression

  2004cited by this paper
• Targeted histone deacetylase inhibition for cancer therapy.

  2004cited by this paper
• S100A11 gene identified by in-house cDNA microarray as an accurate predictor of lymph node metastases of gastric cancer.

  2004cited by this paper
• Targeted histone deacetylase inhibition for cancer therapy.

  2004cited by this paper
• Impact of novel histone deacetylase inhibitors, CHAP31 and FR901228 (FK228), on adenovirus-mediated transgene expression

  2004cited by this paper
• Mechanisms for ATP-dependent chromatin remodelling: farewell to the tuna-can octamer?

  2004cited by this paper
• Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression

  2003cited by this paper
• Structure, mechanism and regulation of peroxiredoxins.

  2003cited by this paper
• Three-Field Lymph Node Dissection for Squamous Cell and Adenocarcinoma of the Esophagus

  2002cited by this paper
• Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo.

  2002cited by this paper
• Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial.

  2002cited by this paper
• Pag, a Putative Tumor Suppressor, Interacts with the Myc Box II Domain of c-Myc and Selectively Alters Its Biological Function and Target Gene Expression*

  2002cited by this paper
• Histone acetyltransferases: function, structure, and catalysis.

  2001cited by this paper
• Translating the Histone Code

  2001cited by this paper
• p300 Collaborates with Sp1 and Sp3 in p21 waf1/cip1 Promoter Activation Induced by Histone Deacetylase Inhibitor*

  2000cited by this paper
• Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites

  2000cited by this paper
• Suberoylanilide Hydroxamic Acid as a Potential Therapeutic Agent for Human Breast Cancer Treatment

  2000cited by this paper
• Peroxiredoxin I expression in oral cancer: a potential new tumor marker.

  2000cited by this paper
• Transcription Factor ZBP-89 Cooperates with Histone Acetyltransferase p300 during Butyrate Activation of p21 waf1 Transcription in Human Cells*

  2000cited by this paper
• Histone acetylases and deacetylases in cell proliferation.

  1999cited by this paper
• Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy

  1999cited by this paper
• Histone Deacetylase 1 Can Repress Transcription by Binding to Sp1

  1999cited by this paper
• Modifying chromatin and concepts of cancer.

  1999cited by this paper
• Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells.

  1999cited by this paper
• Depsipeptide ( FR 901228 ) : A Novel Therapeutic Agent With Selective , In Vitro Activity Against Human B-Cell Chronic Lymphocytic Leukemia Cells

  1999cited by this paper
• Sp3, but not Sp1, mediates the transcriptional activation of the p21/WAF1/Cip1 gene promoter by histone deacetylase inhibitor.

  1999cited by this paper
• Is combined chemotherapy and radiation therapy equally effective as surgical resection in localized esophageal carcinoma?

  1999cited by this paper
• Cloning of a GADD34-like gene that interacts with the zinc-finger transcription factor which binds to the p21(WAF) promoter.

  1999cited by this paper
• Effects of p21Cip1/Waf1 at Both the G1/S and the G2/M Cell Cycle Transitions: pRb Is a Critical Determinant in Blocking DNA Replication and in Preventing Endoreduplication

  1998cited by this paper
• FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor.

  1998cited by this paper
• Erratum: Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication (Molecular and Cellular Biology 18:1 (629))

  1998cited by this paper
• Effect of surgical experience on results of esophagectomy for esophageal carcinoma

  1997cited by this paper
• Crystal structure of the nucleosome core particle at 2.8 Å resolution

  1997cited by this paper
• Butyrate Activates the WAF1/Cip1 Gene Promoter through Sp1 Sites in a p53-negative Human Colon Cancer Cell Line*

  1997cited by this paper
• Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites.

  1997cited by this paper
• The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity.

  1997cited by this paper
• Organization and chromosomal assignment of two human PAG gene loci: PAGA encoding a functional gene and PAGB a processed pseudogene.

  1994cited by this paper
• FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. II. Structure determination.

  1994cited by this paper
• Cloning and sequencing of thiol-specific antioxidant from mammalian brain: alkyl hydroperoxide reductase and thiol-specific antioxidant define a large family of antioxidant enzymes.

  1994cited by this paper
• FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity.

  1994cited by this paper
• A human cDNA corresponding to a gene overexpressed during cell proliferation encodes a product sharing homology with amoebic and bacterial proteins.

  1993cited by this paper

• PRDX1 knockdown promotes erastin-induced ferroptosis and impedes diffuse large B-cell lymphoma development by inhibiting the MAPK/ERK pathway

  2025cites this paper
• Redox guardian or oncogenic driver? The dual roles of PRDX1 in tumorigenesis.

  2025cites this paper
• O-GlcNAcylation of PRDX1 enhances its stability and promotes liver cancer progression via activating LRP6-mediated Wnt signaling.

  2025cites this paper
• Attenuation of neuronal ferroptosis in intracerebral hemorrhage by inhibiting HDAC1/2: Microglial heterogenization via the Nrf2/HO1 pathway

  2024cites this paper
• Romidepsin exhibits anti-esophageal squamous cell carcinoma activity through the DDIT4-mTORC1 pathway

  2024cites this paper
• The interaction of PRDX1 with Cofilin promotes oral squamous cell carcinoma metastasis

  2024cites this paper
• The Role of Epigenetic Mechanisms in the Treatment of GI Cancers.

  2024cites this paper
• Epigenetic modifications in esophageal cancer: An evolving biomarker

  2023cites this paper
• Expression And Prognostic Role of PRDX1 In Gastrointestinal Cancers

  2023cites this paper
• Super-enhancers in esophageal carcinoma: Transcriptional addictions and therapeutic strategies

  2022cites this paper
• Histone deacetylase inhibitors (HDACi), the ongoing epigenetic agents to enhance chemotherapy sensitization

  2021cites this paper
• Targeted Exosomes for Drug Delivery: Biomanufacturing, Surface Tagging, and Validation

  2020cites this paper
• Epigenetics in Esophageal Cancer: From Mechanisms to Therapeutics

  2020cites this paper
• Targeting Epigenetic Aberrations in Esophageal Squamous Cell Carcinoma

  2020cites this paper
• Prdx1 Reduces Intracerebral Hemorrhage-Induced Brain Injury via Targeting Inflammation- and Apoptosis-Related mRNA Stability

  2020cites this paper
• Genome-wide ChIP-seq data with a transcriptome analysis reveals the groups of genes regulated by histone demethylase LSD1 inhibition in esophageal squamous cell carcinoma cells

  2019influential citation
• Natural Cyclic Peptides as an Attractive Modality for Therapeutics: A Mini Review

  2018cites this paper
• Epigenetic regulation of peroxiredoxins: Implications in the pathogenesis of cancer

  2017cites this paper
• 3-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity.

  2017cites this paper
• Pro-Apoptotic Effects of JDA-202, a Novel Natural Diterpenoid, on Esophageal Cancer Through Targeting Peroxiredoxin I

  2017cites this paper
• 11-14-2008 Epigenetics in the nervous system

  2017cites this paper
• EXPLORATION OF THE SRX-PRX AXIS AS A SMALL-MOLECULE TARGET

  2016cites this paper
• Peroxiredoxin 1 – an antioxidant enzyme in cancer

  2016cites this paper
• Expression and clinical value of peroxiredoxin-1 in patients with pancreatic cancer.

  2015cites this paper
• Usefulness of microRNA‑375 as a prognostic and therapeutic tool in esophageal squamous cell carcinoma.

  2015cites this paper
• Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine

  2015cites this paper
• The sulfiredoxin-peroxiredoxin (Srx-Prx) axis in cell signal transduction and cancer development.

  2015cites this paper
• 1-Arylsulfonyl-5-(N-hydroxyacrylamide)tetrahydroquinolines as potent histone deacetylase inhibitors suppressing the growth of prostate cancer cells.

  2015cites this paper
• Histone Demethylase LSD1 Inhibitors Prevent Cell Growth by Regulating Gene Expression in Esophageal Squamous Cell Carcinoma Cells

  2015cites this paper
• Screening of Alternative Drugs to the Tumor Suppressor miR-375 in Esophageal Squamous Cell Carcinoma Using the Connectivity Map

  2014cites this paper
• Epigenetics in esophageal cancers

  2014cites this paper
• Tuning of Peroxiredoxin Catalysis for Various Physiological Roles

  2014cites this paper
• Natural product chemistry and anticancer drug discovery

  2014cites this paper
• Diagnostic and prognostic significance of peroxiredoxin 1 expression in human hepatocellular carcinoma

  2013cites this paper
• MicroRNAs in cancer diagnosis and therapy: from bench to bedside

  2013cites this paper
• Peroxiredoxin 1 is a tumor-associated antigen in esophageal squamous cell carcinoma

  2013cites this paper
• Proteomic investigation of the molecular targets of mycophenolic acid in human cells

  2012cites this paper
• Identification of novel molecular targets regulated by tumor suppressive miR-375 induced by histone acetylation in esophageal squamous cell carcinoma.

  2012cites this paper
• Differential proteome analysis of human embryonic kidney cell line (HEK-293) following mycophenolic acid treatment

  2011cites this paper
• Dietary Chemoprevention Agent Sulforaphane Inhibits Growth, Survival and Tumorigenic Activity in Human Neuroblastoma

  2010cites this paper
• Peroxiredoxin 1 Is Required for Efficient Transcription and Replication of Measles Virus

  2010cites this paper
• Recent advances in histone deacetylase targeted cancer therapy

  2010cites this paper
• Peroxiredoxin 1 is Required for the Efficient Transcription and Replication of 1 Measles Virus 2 3

  2010cites this paper
• Typical 2‐Cys peroxiredoxins – modulation by covalent transformations and noncovalent interactions

  2009cites this paper
• New treatment strategies for Hodgkin's lymphoma.

  2009cites this paper
• Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas -deficient MRL/lpr(-/-) murine model of autoimmune lymphoproliferative syndrome (ALPS).

  2009cites this paper
• Effects of carbon-ion radiotherapy combined with a novel histone deacetylase inhibitor, cyclic hydroxamic-acid-containing peptide 31 in human esophageal squamous cell carcinoma.

  2009cites this paper
• CHAPTER 5 – Natural product chemistry and anticancer drug discovery

  2008cites this paper
• Characterization and expression of Peroxiredoxin 1 in the neonatal tammar wallaby (Macropus eugenii).

  2008cites this paper
• Epigenetics in the Nervous System

  2008cites this paper
• Application of partial least squares discriminant analysis and variable selection procedures: a 2D-PAGE proteomic study

  2008cites this paper
• Gene microarray analysis of human renal cell carcinoma: The effects of HDAC inhibition and retinoid treatment

  2008cites this paper
• Trichostatin A regulates peroxiredoxin expression and virulence of the parasite Entamoeba histolytica.

  2008cites this paper
• Tandem immunoprecipitation of phosphotyrosine-mass spectrometry (TIPY-MS) indicates C19ORF19 becomes tyrosine-phosphorylated and associated with activated epidermal growth factor receptor.

  2008cites this paper
• A proteomic approach for evaluating the cell response to a novel histone deacetylase inhibitor in colon cancer cells.

  2008cites this paper
• Role of histone deacetylase inhibitor in adenovirus-mediated p53 gene therapy in esophageal cancer.

  2008cites this paper
• Epigenetic aberrations and targeted epigenetic therapy of esophageal cancer.

  2008cites this paper
• Proteomic analysis of pancreatic endocrine tumor cell lines treated with the histone deacetylase inhibitor trichostatin A

  2007cites this paper
• Novel targeted therapies for advanced esophageal cancer.

  2007cites this paper
• Gene expression profiling induced by histone deacetylase inhibitor, FK228, in human esophageal squamous cancer cells.

  2007cites this paper
• Tumor suppressor Prdx1 is a prognostic factor in esophageal squamous cell carcinoma patients.

  2007cites this paper
• The pancreatic cancer proteome – recent advances and future promise

  2007cites this paper
• FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities

  2006cites this paper
• Tumor suppressor Prdx 1 is a prognostic factor in esophageal squamous cell carcinoma patients

  year unknowncites this paper